Dermatologicals is expected to be largely unaffected by COVID-19, with similar healthy double-digit value growth as 2019. However, part of this growth in 2020 is driven by inflation as a result of the economic effect of COVID-19, which has led to some price rises.
Local players account for a sizeable value share in dermatologicals in Nigeria, with Neimeth retaining its strong leadership position in terms of value share in 2020, thanks to its brands Tiocosid, Flucosyd, Gyno-Tiocosid, Tiocosid (vaginal antifungals) and TCP (topical germicidals/antiseptics). Second placed is another local manufacturer Gemini Pharmaceuticals, whose leading brand is antifungal cream, Sabresten.
Chemists/pharmacies remains the leading distribution channel for dermatologicals in Nigeria, and although dermatologicals can be distributed through drugstores/parapharmacies, chemist/pharmacies remains the fastest growing retail channel for the distribution of these products. There has also been an increase in the number of chemists/pharmacies across the country especially in urban areas, leading to chemists/pharmacies retaining its position among other distribution channels.
COVID-19 did not significantly affect value sales in dermatologicals and overall, dermatologicals is expected to continue as normal over the forecast period. However, this masks some variations in the prospects of certain products.
One of the key factors driving growth in nappy (diaper) rash treatments is population growth. Nigeria’s enormous population means that there are huge numbers of babies being born in the country every year and this continues to support strong growth in sales of nappy (diaper) rash treatments.
Topical antifungals is the biggest product area and is expected to post double-digit current value growth in 2020 and this strong growth is expected to continue over the forecast period. Factors such as dirty water, unsanitary conditions, pollution, sexually transmitted infections and unhealthy lifestyles will continue to drive value sales.
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
Understand the latest market trends and future growth opportunities for the Medicated Skin Care industry in Nigeria with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Medicated Skin Care industry in Nigeria, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
This report originates from Passport, our Medicated Skin Care research and analysis database.
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE! Home Page